Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (noting a discrepancy with the metadata request for "Avalo Therapeutics, Inc.") on May 18, 2016. The filing documents the results of the Company's Annual Meeting of Stockholders held on that date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
As of the record date (March 31, 2016), there were 8,650,143 shares of common stock outstanding. Approximately 55% of eligible voting shares (4,748,095 shares) were represented at the meeting. Stockholders approved the following proposals:
- Proposal 1 (Director Elections): Eugene A. Bauer, M.D., and Magnus Persson, M.D., Ph.D., were elected to the Board of Directors.
- Proposal 2 (Equity Incentive Plan): The Cerecor Inc. 2016 Equity Incentive Plan (2016 EIP) was approved.
- Proposal 3 (Employee Stock Purchase Plan): The Cerecor Inc. 2016 Employee Stock Purchase Plan (2016 ESPP) was approved.
- Proposal 4 (Auditor Ratification): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016, was ratified.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. It references the full text of the 2016 EIP and 2016 ESPP filed as Exhibits 10.1 and 10.2 for complete details on compensatory arrangements.
Investor Verification Checklist
- Verify the correct registrant name (Cerecor Inc. vs. Avalo Therapeutics, Inc.) in the context of the investment thesis.
- Review Exhibits 10.1 and 10.2 for the specific terms, share limits, and vesting schedules of the newly approved equity plans.
- Confirm the tenure of the newly elected directors (Eugene A. Bauer and Magnus Persson) until the 2019 Annual Meeting.
- Check subsequent filings for the impact of the new equity plans on share dilution.